Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study-Reference-Cited by-同舟云学术

Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study

Published:2017 Issue:4 Volume:6 Page:313-324
ISSN:2235-1795
Container-title:Liver Cancer
language:en
Short-container-title:Liver Cancer

Author:

Yen Clarence,Sharma Rohini,Rimassa Lorenza,Arizumi Tadaaki,Bettinger Dominik,Choo Huay Yee,Pressiani Tiziana,Burlone Michela E.,Pirisi Mario,Giordano Laura,Abdulrahman Anisa,Kudo Masatoshi,Thimme Robert,Park Joong Won,Pinato David James

Publisher

S. Karger AG

Subject

Oncology,Hepatology

Reference33 articles.

1. Ferlay J, Soerjomataram I, Dikshit R, et al: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386.

2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.

3. Dhir M, Melin AA, Douaiher J, et al: A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg 2016;263:1112-1125.

4. Leoni S, Piscaglia F, Serio I, et al: Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. Dig Liver Dis 2014;46:549-555.

5. Park JW, Chen M, Colombo M, et al: Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015;35:2155-2166.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept;The Lancet Oncology;2023-07

2. Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment;JGH Open;2023-04

3. Trial Designs for Integrating Novel Therapeutics into the Management of Intermediate-Stage Hepatocellular Carcinoma;Journal of Hepatocellular Carcinoma;2022-06

4. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC;Hepatology Communications;2022-04-28

5. PBLD inhibits angiogenesis via impeding VEGF/VEGFR2-mediated microenvironmental cross-talk between HCC cells and endothelial cells;Oncogene;2022-02-10